In a significant advancement for renewable energy technology, researchers at the École Polytechnique Fédérale de Lausanne (EPFL) have successfully addressed…
Read More
Eli Lilly’s Triple Agonist Retatrutide Achieves Remarkable 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes
Eli Lilly and Company has announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk’s investigational triple agonist, UBT251, has demonstrated a mean weight loss of 19.7% after 24 weeks in a Phase…
Read More
Breakthrough in Osmotic Energy Harvesting EPFL Researchers Utilize Lipid-Coated Nanopores to Triple Blue Energy Efficiency
Researchers at the Ecole Polytechnique Fédérale de Lausanne (EPFL) have announced a significant leap in the field of renewable energy…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read MoreYOU MAY HAVE MISSED
